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Recently we identified a novel target gene of MEF2A named myospryn that encodes a large, muscle-specific, costamere-restricted α-actinin
binding protein. Myospryn belongs to the tripartite motif (TRIM) superfamily of proteins and was independently identified as a dysbindin-
interacting protein. Dysbindin is associated with α-dystrobrevin, a component of the dystrophin–glycoprotein complex (DGC) in muscle. Apart
from these initial findings little else is known regarding the potential function of myospryn in striated muscle. Here we reveal that myospryn is an
anchoring protein for protein kinase A (PKA) (or AKAP) whose closest homolog is AKAP12, also known as gravin/AKAP250/SSeCKS. We
demonstrate that myospryn co-localizes with RIIα, a type II regulatory subunit of PKA, at the peripheral Z-disc/costameric region in striated
muscle. Myospryn interacts with RIIα and this scaffolding function has been evolutionarily conserved as the zebrafish ortholog also interacts with
PKA. Moreover, myospryn serves as a substrate for PKA. These findings point to localized PKA signaling at the muscle costamere.
© 2007 Elsevier B.V. All rights reserved.Keywords: MEF2 target; Muscle-specific; Tripartite motif; Scaffolding protein; Costamere; Protein kinase A1. Introduction
Myocyte enhancer factor-2 (MEF2) functions as an impor-
tant regulator of cell proliferation and differentiation in multiple
tissues by coordinately regulating the expression of a broad
spectrum of genes [1,2]. Studies have revealed that components
of signal transduction pathways represent a significant fraction
of the total number of genes regulated by MEF2 [3–6].
Consistent with these observations is the finding that expression
of the stress-responsive protein kinase MKK6, the G-protein
signaling effector RGS2, and the calcium regulated serine/
threonine protein phosphatase calcineurin genes is deregulated
in hearts lacking MEF2A [7].
The cAMP-protein kinase A (PKA) signal transduction
pathway has been extensively characterized and plays an
important role in muscle function and disease [8,9]. Despite the
ubiquity of PKA signaling in cells, specificity is achieved via
the recruitment of the kinase to distinct subcellular regions by⁎ Corresponding author. Tel.: +1 617 353 2469; fax: +1 617 353 6340.
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doi:10.1016/j.bbamcr.2007.04.004scaffolding proteins known as A-kinase anchoring proteins
(AKAPs) [10–12]. Tethering of PKA by AKAPs enables PKA
to phosphorylate a target within a specific location in the cell.
For instance, in striated muscle PKA signaling plays a central
role in contractility via the phosphorylation of the ryanodine
receptor (RyR) resulting in Ca2+-induced Ca2+-release from the
sarcoplasmic reticulum during excitation–contraction coupling
[13]. Recruitment of PKA to the sarcoplasmic reticulum is
coordinated through the scaffolding function of muscle AKAP
(mAKAP) which is localized to the sarcoplasmic reticulum and
the neighboring perinuclear membrane where it forms a
complex with the ryanodine receptor [14,15]. While additional
AKAPs are also expressed in muscle [16], to date, mAKAP is
the only known muscle-specific PKA anchoring protein.
Previouslywe demonstrated that themuscle-specificmyospryn
gene is a direct MEF2 target [17]. The myospryn gene product
harbors a tripartite motif (TRIM) and is localized to the costamere
of striated muscle where it interacts with α-actinin and dysbindin
[17–19]. The TRIM domain is encoded by the 550 C-terminal
amino acids of the protein and is the only knownmotif in this large
protein of 3739 amino acids. Because myospryn function remains
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identify additional biochemical and structural information on the
protein. One of these searches revealed similarity between
myospryn and a PKA anchoring protein, AKAP12, also known
as gravin/AKAP250/SSeCKS (Src-suppressedC kinase substrate)
[20,21]. Through functional domain mapping we show that
myospryn harbors three bona-fide PKA-anchoring domains that
bind toRIIα, a type II regulatory subunit of PKA. Furthermore,we
show that myospryn co-localizes with RIIα at the costameric
region overlying the Z-disc in striated muscle. Thus, myospryn
represents a novel muscle-specific AKAP and the first to be
localized to the costamere in striatedmuscle. Myospryn is also the
first example of a protein in the TRIM superfamily that can
function as a scaffold for protein kinases. The ability of myospryn
to recruit PKA to the costamere may enable the cAMP signal
transduction pathway to regulate proteins within this important
subcellular structure in muscle.
2. Materials and methods
2.1. Plasmids
For coimmunoprecipitation assays the following expression vectors were
constructed:
Flag-tagged PKA-subunit constructs in the pcDNA3.1 vector, Flag-RIα, Flag-
RIIα, Flag-RIβ, and Flag-RIIβ, along with various Myc-tagged myospryn
constructs (described in Fig. 5) also in the pcDNA3.1 vector backbone. For GST
pulldown assays, RIIα was cloned into pGEX-2T-KG. For subcellular location
studzies in COS cells, NLS-RIIα was generated by cloning the following nuclear
localization signal in pCDNA3-RIIα: MAPKKKRKV; 5′-atg gct cca aag aag aag
cgt aag gta-3′.
2.2. Cell culture, co-immunoprecipitations and GST pulldown assays
COS1 cells were grown in 6-cm dishes using DMEM supplemented with
10% Fetal Bovine Serum, 1% Penicillin/Streptomycin, and 1% L-Glutamine.
COS1 cells were transfected with 6.0 μg total DNA using Mirus TransIT-LT1
transfection reagent. Forty-eight hours post-transfection, cells were washed in
1× PBS, pelleted and subsequently homogenized in 500 μl ELB Buffer (0.05 M
HEPES, 0.25 M NaCl, 0.005 M EDTA, 0.1% NP40, 1 mM PMSF, 1 mM DTT,
and 1× Roche protease inhibitor cocktail solution). Homogenized cells were
incubated on ice for 10 min, and centrifuged at 4 °C for 10 min at 13,000 rpm.
Protein extracts were added to 20 μl of pre-washed Protein G-Sepharose beads
(Amersham Biosciences) pre-incubated with 2.0 μg of either anti-Flag or anti-
Myc antibodies and immunoprecipitated for 2 h at 4 °C. Beads were washed
three times in ELB Buffer and re-suspended in one bed volume of SDS sample
loading buffer containing 1% β-mercaptoethanol. Samples were fractionated on
10% SDS-PAGE gels and blotted on Immun-blot PVDF membrane (BioRad).
Membranes were immunoblotted with 0.2 μg/ml primary antibody, followed by
HRP-conjugated secondary antibodies and reacted with Western Lightning
chemiluminescent reagent (Perkin Elmer). Anti-FLAG® M2 monoclonal
antibody (Sigma) was used to detect Flag-tagged PKA constructs. c-Myc
(9E10) mouse monoclonal antibody (Santa Cruz Biotechnology) was used to
detect Myc-tagged myospryn constructs. Goat-anti-mouse HRP conjugated
secondary antibodies (Perkin Elmer) were used for detection of proteins for
western blotting.
For endogenous immunoprecipitations, COS cells were transfected with
pcDNA3-Myc or Myc-Spe as described above. Immunoprecipitated protein
extracts were analyzed for the presence of PKA by immunoblotting using
mouse-anti-PKA-C (catalytic) antibody (BD Transduction Laboratories) to
detect endogenous protein.
GST pulldown assays. GST alone and GST-RIIα were expressed in
Escherichia coli DH5α cells and purified. Thirty micrograms of protein was
added to glutathione sepharose beads and incubated at 4 °C for 2 h. Totalprotein from COS cells transfected with Myc-Spe was added to GST protein
and beads and incubated at 4 °C for 2 h, washed with ELB buffer to remove
non-specific interactions and loaded and immunoblotted with the anti-Myc
antibody.
2.3. Immunohistochemistry
Adult mice were perfused with 4% paraformaldehyde, hindlimb muscles
were dissected and cryoprotected in 30% sucrose (in 1× PBS) at 4 °C prior
to embedding. Hindlimb muscle was embedded in OCT compound (Tissue-
Tek), sectioned at 15 μM, and air-dried onto Superfrost plus glass slides
(Fisher). Primary antibody to detect PKA RII-subunits was added at a 1:40
dilution in blocking solution (1× PBS containing 3% BSA) and allowed
to incubate overnight at 4 °C. Following overnight incubation, primary
antibodies for myospryn were diluted 1:100 in blocking solution (3% normal
horse serum in 1× PBS) and incubated for 1 h at room temperature.
Secondary antibodies (1:500 dilution) were added to each slide and
incubated for 1 h at room temperature. Slides were washed in 1× PBS,
followed by addition of Vectashield mounting medium (Vector Labs), and
cover slips were applied and sealed before imaging on light microscope.
Goat polyclonal anti-PKA-RII subunit antibodies (Upstate Biotechnology)
were used to detect RII protein in both the co-immunostain and RII-alone
stained control. Rabbit polyclonal antibodies for myospryn were generated as
previously described [17]. Donkey anti-rabbit-Texas Red antibodies (Santa
Cruz Biotechnology) were used to detect primary rabbit anti-myospryn
antibodies on skeletal muscle sections. Chicken anti-goat FITC-conjugated
antibodies (Santa Cruz Biotechnology) were used to detect goat polyclonal
anti-PKA RII antibodies.
COS cells were transfected with 2.0 μg of RIIα, NLS-RIIα, or Myc-Spe or
cotransfected with 1.0 μg each of NLS-RIIα and Myc-Spe. Forty eight hours
post-transfection, cells were fixed with 4% paraformaldehyde for 10 min at
room temperature, washed with 1× PBS and incubated for 10 min with blocking
solution at room temperature. Primary antibody to detect PKA-RII or Myc was
added at a 1:200 dilution in blocking buffer and incubated for 1 h at room
temperature. Cells were washed with 1× PBS and incubated with chicken anti-
goat IgG FITC (Santa Cruz Biotechnology) to detect primary goat-anti-PKA-RII
antibodies or Texas Red anti-mouse IgG (Vector Labs) to detect mouse-anti-Myc
antibodies at a 1:200 dilution in 1× PBS with 0.1% IGEPAL for 1 h. Cells were
washed with 1× PBS and followed by addition of Vectashield mounting medium
containing DAPI (Vector Labs), and cover slips were applied and sealed before
imaging on light microscope.
2.4. In vitro kinase assay
Epitope-tagged plasmids were transfected into COS cells grown in 6-cm
dishes. Forty-eight hours post-transfection cells were harvested, lysed and
immunoprecipitated using the desired antibody as described. Samples were
incubated with 2 μl of supplied 10× Reaction Buffer, 10 μCi of g-P32ATP, and
1 μl purified cAMP-dependent protein kinase (PKA) catalytic subunit (New
England Biolabs), and incubated at 30 °C for 30 min. For PKA specificity
experiments reactions were treated with the PKA peptide inhibitor, PKI
(Promega). Samples were fractionated in 10% SDS-PAGE, dried onto Whatman
paper and exposed to a phosphoimager.
3. Results
3.1. Sequence similarity between myospryn and AKAP12
The muscle-specific protein, myospryn harbors a TRIM
region [19] located in the carboxy-terminal 550 amino acids of
the full-length protein (3,739 amino acids) leaving well over
3,000 amino acids of the protein uncharacterized. In an effort to
gain insight into the potential function of myospryn in muscle
we searched various protein motif databases for further
structural information on the protein. One such protein family
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similarity between myospryn and AKAP12 (data not shown).
AKAP12 is a member of the AKAP superfamily which bind to
the regulatory subunits of PKA thereby acting as downstream
scaffolds for the cAMP signaling pathway [10–12]. AKAP12,
also known as gravin/AKAP250/SSeCKS, the human and
mouse homologs, respectively, is a ubiquitously expressed,
cytoplasmic scaffold for PKA [19,20]. As shown in Fig. 1A,
myospryn (amino acids 1,428–3,030) and gravin (amino acids
216–1,755) exhibit 18% identity and 35% similarity within a
region spanning 1,500 amino acids. The modest similarity of
myospryn to this AKAP prompted us to test for an interaction
with PKA.Fig. 1. Sequence similarity between myospryn and gravin. (A) Bioinformatics anal
identity and 35% positive similarity with the PKA anchoring protein gravin/AKAP1
amino acids 1540 through 1553. (B) Coimmunoprecipitation of RIIα with the carbo
while an amino-terminal construct containing amino acids 1370 through 3096 is unab
3739 (Spe) is capable of interacting with RIIα. Immunoblot of Myc-immunoprecipita
(C) GST pulldown assay. Protein extracts from COS cells transfected with Myc-Sp
sepharose beads. Reactions were subjected to SDS-PAGE and immunoblotted usin
Coimmunoprecipitation of the four regulatory subunits demonstrates that myospryn is
antibody and immunoblotted with anti-Myc (for myospryn) and anti-FLAG (for regu3.2. Myospryn interacts with the type II regulatory subunit of
PKA
To establish that myospryn binds to PKA we co-expressed
epitope tagged Myc-myospryn and individual FLAG-PKA
subunits in COS cells and tested for interaction by co-
immunoprecipitation (co-IP). For these experiments we initially
tested the type II regulatory subunit of PKA (RIIα), since it
binds to most of the known AKAPs [22]. Total protein extracts
from transfected cells were incubated in the presence of anti-
Myc antibody and protein G sepharose beads and the
immunoprecipitations were subjected to Western blot analysis
using an anti-FLAG antibody. As shown in Fig. 1B, theseysis revealed that myospryn (amino acids 1428–3030) shares 18% amino acid
2 (amino acids 216–1755). The RIIα interaction domain for gravin is located at
xy-terminus of myospryn. Full-length myospryn is shown to interact with RIIα,
le to interact. A carboxy-terminal fragment containing amino acids 2965 through
ted constructs detecting the presence of FLAG-RIIα. The IgG band is indicated.
e was added to bacterially expressed GST or GST-RIIα bound to glutathione
g an anti-Myc antibody. (D) PKA regulatory subunit specificity for myospryn.
an RIIα-selective AKAP. Immunoprecipitations were performed using anti-Myc
latory subunits).
Fig. 2. Myospryn and RIIα interact in intact cells. (A) RIIα and NLS-RIIα were transfected into COS cells and immunostained using an anti-RII antibody. RIIα
exhibits a cytoplasmic/perinuclear localization whereas NLS-RIIα is shuttled into the nucleus. DAPI staining indicates the location of the nuclei. Arrows demonstrate
representative cells. (B) COS cells transfected with Myc-Spe alone or cotransfected with NLS-RIIα and Myc-Spe. Myc-Spe alone exhibits a cytoplasmic staining
pattern. Cotransfection with NLS-RIIα, Myc-Spe is shuttled into the nucleus demonstrating an in vivo association with this regulatory subunit of PKA. DAPI staining
indicates the location of the nuclei. (C) Myospryn precipitates PKA from COS cells. COS cells were transfected with pcDNA3-Myc or Myc-Spe. Protein extracts were
immunoprecipitated using the anti-Myc antibody and immunoblotted for endogenous PKA using antibodies directed against catalytic subunit (PKA-C, BD
Transduction Laboratories). Protein extracts loaded and blotted with the anti-PKA-C antibody detected the presence of similar amounts of PKA-C in both samples.
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capable of interacting with the RIIα subunit of PKA in COS
cells. pcDNA3-Myc vector and Myc-SSeCKS served as
negative and positive controls respectively for RIIα binding
(data not shown). As an initial step for locating the interaction
region we tested the ability of two different myospryn
constructs, an amino-terminal myospryn construct (aa 1370–
3096) and a carboxy-terminal fragment (aa 2965–3739), to
interact with RIIα. The amino-terminal myospryn fragment did
not immunoprecipitate with RIIα whereas the carboxy-terminalSpe fragment of myospryn interacted effectively with RIIα
(Fig. 1B). The above results are the first demonstration that
myospryn interacts with PKA in a region encompassing amino
acids 3,096 and 3,739.
To verify the above association myospryn and RIIα were
subjected to GST pulldown experiments. Recombinant GST-
RIIα coupled to glutathione sepharose beads effectively pre-
cipitated the myospryn carboxy-terminal fragment (Fig. 1C).
This interaction was specific since GST alone was unable to
immunoprecipitate myospryn. Taken together, the mamma-
Fig. 3. Co-localization of myospryn and RIIα in striated muscle. (A) Double immunohistochemistry on longitudinal sections from mouse hindlimb muscle. Upper
panel, muscle sections using anti-myospryn antibodies shows a striated pattern of expression (red) as previously demonstrated. Middle panel, anti-RII antibodies reveal
a striated pattern of expression as previously reported. Bottom panel, when the above two images are superimposed a yellow striated signal is readily apparent
demonstrating co-localization of myospryn and RIIα. (B) Immunohistochemistry on transverse skeletal muscle. Double immunohistochemistry demonstrates co-
localization of myospryn and RIIα along periphery of skeletal muscle fibers.
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myospryn and PKA interact under various experimental
conditions.
The AKAP superfamily is generally categorized into two
classes: 1) members which bind to a single type of regulatory (R)
subunit designated as type I or type II (single specificity) or 2)
members that bind to both the type I and type II regulatory
subunits (dual-specificity) [10]. Therefore, we tested whether
myospryn could bind to additional R subunits of PKA using co-
IP as described above. The remaining PKA regulatory subunits,
type I (RIα and RIβ) and type II (RIIβ) were cloned into FLAG-
tagged expression vectors and co-transfected individually along
with the carboxy-terminal Myc-tagged Spe fragment in COS
cells. As shown in Fig. 1D, the carboxy-terminal region of
myospryn was unable to interact with the other PKA regulatory
subunits. Thus myospryn, like AKAP12, interacts specificallywith the RIIα subunit of PKA and can thus be considered a type
II single-specificity anchoring protein for PKA.
3.3. Myospryn and RIIα interact in intact cells
To demonstrate that myospryn and RIIα interact in intact cells
we tested whether a nuclear localized form of RIIα could recruit
myospryn to the nucleus. Myospryn and RIIα are typically
distributed in the cytoplasm when expressed individually in
COS cells (Fig. 2A, upper left panel and Fig. 2B, middle lower
panel). Therefore, for these experiments we designed an RIIα
expression vector harboring a strong nuclear localization signal
(NLS). As shown in Fig. 2A, RIIαwhich normally resides in the
cytoplasm (upper panels) is directed to the nucleus as a NLS-
RIIα fusion protein (lower panels). When the NLS-RIIα
expression vector was used in co-transfection experiments,
Fig. 4. Mapping of the RIIα-binding site of myospryn. (A) Coimmunoprecipitation demonstrating the identification of an RIIα interaction domain. Upper panel,
progressive Myc-tagged carboxy-terminal myospryn deletions were cotransfected with FLAG-tagged RIIα, and immunoprecipitated with the Myc antibody and
immunoblotted with the FLAG antibody detecting the presence of RIIα. Bottom panel, protein extracts loaded and immunoblotted using the anti-Myc antibody
detecting proper expression of the myospryn constructs. Protein extracts loaded and blotted with the anti-FLAG antibody detected similar expression levels of the RIIα
construct (not shown). (B) Identification of a third amphipathic helix in myospryn. Removal of two amphipathic helices fails to disrupt interaction with RIIα.
Additional deletion constructs reveal the presence of a third amphipathic helix. (C) Mutational analysis of three amphipathic helices in myospryn. Introduction of point
mutations in the proposed amphipathic helices H1 and H2. Replacement of leucine 3197 with a proline contained within H1 results in the inability of that construct to
interact with RIIα, demonstrated by co-IP. Replacement of leucine 3309 with a proline within H2 results in an inability of that construct to interact with RIIα as well.
Replacement of cysteine with a proline in H3 severely diminishes interaction with RIIα. (D) Helical wheel representation of the three amphipathic helices. Shown is a
clustering of hydrophobic residues (shaded) on one face of the helix and hydrophilic residues (unshaded) on the opposite face.
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compare upper left and middle panels to lower middle panel).
We also tested for an endogenous interaction between the two
proteins. Myospryn antibodies are unable to immunoprecipitate
native myospryn from muscle under standard conditions
precluding our ability to analyze endogenous complex formation.
Instead, we transfected aMyc-myospryn construct into COS cells
and tested its ability to precipitate endogenous PKA. As shown in
Fig. 2C, Myc-myospryn immunoprecipitated endogenous PKA
from COS cells whereas overexpression of pcDNA3-Myc alonewas unable to do so. The above results reinforce the notion of a
myospryn–PKA interaction in mammalian cells.
3.4. Myospryn and RIIα colocalize in striated muscle
AKAPs are found at specific subcellular compartments which
serves to direct PKA enzymatic activity in close proximity to its
target substrate(s). Previously published reports described a Z-
disc pattern of localization for RIIα in striated muscle [23,24]. In
addition, it has been shown that myospryn localizes to the
Fig. 5. (A) Schematic diagram of selectMyc-taggedmyospryn constructs expressed inCOS cells tomap theRIIα-binding domain. Interactions results are shown at right (+,
positive interaction; −, negative interaction). (B) Schematic depiction of the three PKA anchoring motifs in relation to the TRIM region of myospryn. The H1 helix is
localized immediately upstream of the TRIM region; H2 is found within the B-box coiled coil (BBC) domain; and H3 is situated within the first fibronectin 3 repeat (FN3).
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the Z-disc [17,18]. To determine whether myospryn and RIIα
co-localize at the costameric region in striated muscle we
performed double-label immunohistochemistry on adult mouse
skeletal muscle longitudinal sections with antibodies directed
against myospryn [17] and the type II regulatory subunit
(Upstate Biotechnology). As demonstrated in our previous
study, myospryn exhibits a periodic staining pattern in
longitudinal sections reflecting localization that is in register
with the Z-disc (Fig. 3A, upper panel). Similarly, the RII-specific
antibodies exhibited a periodic staining pattern (Fig. 3A, middle
panel) consistent with previous data. When these images were
superimposed the fluorescent label turned yellow specifically at
the Z-disc indicative of co-localization (Fig. 3A, bottom panel).
In a complementary set of experiments we performed double
label immunohistochemistry on transverse skeletal muscle
sections. As shown in Fig. 3B, myospryn and RII are co-localized along the periphery of muscle fibers. These results
reveal that myospryn and the PKA RIIα subunit are present in
the same subcellular compartment in striated muscle in vivo,
reinforcing the notion that myospryn localizes PKA signaling to
the peripheral Z-disc region of striated muscle.
3.5. Identification of three amphipathic helix PKA binding
motifs in myospryn
Given the ability of the carboxy-terminal residues of
myospryn (aa 3096–3739) to bind RIIα, we set out to identify
the minimal PKA interaction domain within this region. It is
worth noting that the PKA docking site in gravin is embedded
within the region of similarity between the proteins yet this
homologous region on myospryn did not bind to PKA. This is
not entirely surprising since few AKAPs exhibit primary amino
acid sequence conservation within their PKA-anchoring
Fig. 6. (A) Sequence alignment of the three PKA anchoring motifs. The carboxy-terminal myospryn fragment Spe possesses significant sequence homology to the
Zebrafish (Danio rerio) myospryn ortholog (aa 894–1161). This region in zebrafish myospryn harbors three proposed RIIα interacting domains. (B) Co-
immunoprecipitation of zebrafish myospryn and RIIα. Like mouse myospryn, zebrafish myospryn is capable of immunoprecipitating RIIα, demonstrating an
evolutionary conservation AKAP function for myospryn.
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14–18 amino acids to form an amphipathic helix that functions
as a high affinity docking site for the R subunits of PKA [10].
Since we identified a large number of predicted α-helices in the
carboxy-terminal region of myospryn we set out to functionally
map the minimal interaction domain between myospryn and
RIIα, using co-IP in COS cells.
We generated numerous amino-terminal, carboxy-terminal,
and internal deletion constructs of the Spe fragment (aa 2965–
3739) of myospryn and tested each one for its ability to bind
RIIα. As shown in Fig. 4A, three progressive carboxy-terminal
deletion constructs in the context of the myospryn Spe
fragment, designated Δ1, Δ2, and Δ3, respectively, interacted
with RIIα. However, an additional deletion construct, CYTC,
(aa 2965–3187) was unable to immunoprecipitate RIIαdemonstrating the existence of a potential PKA docking site
between amino acid 3187 and 3215 of myospryn. Upon
examining the primary amino acid sequence between residues
3187 and 3215 we identified a 17-amino acid sequence,
CKSLVSEMDKALDIHKD, predicted to form an amphipathic
helix when subjected to helical wheel analysis (www.kael.net/
helical_old.htm) (Fig. 4D, left, designated H1). To demonstrate
that interaction with RIIα is occurring through the hydrophobic
region of the predicted helix H1 a mutant construct was
generated consisting of a single amino acid substitution of a
leucine residue with a proline (L3197P) in the context of theΔ3
construct. Introduction of a proline within the hydrophobic face
of the helix is expected to disrupt the helix and interfere with
the ability of myospryn to interact with RIIα. As predicted, the
Δ3-L3197P mutant construct was unable to interact with RIIα
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a minimal amphipathic helix anchoring domain for PKA in
myospryn.
We continued our mapping analysis testing various fragments
within the carboxy-terminal region of myospryn for interaction
with PKA because of two unexpected findings. First, a deletion
constructΔN8.2 lacking the amino-terminal 250 amino acids of
the myospryn Spe fragment (aa 3216–3739), which removes the
aforementioned PKA-anchoring domain H1, interacted with
RIIα (Fig. 5A). Second, an internal deletion within the Δ2
construct, lacking the H1 anchoring domain, also interacted with
RIIα suggesting the presence of an additional PKA anchoring
domain between residues 3216 and 3340. Therefore, we
generated a construct which overlapped with and included
most of these residues (aa 3267–3403). When tested by co-IP,
this region alone interacted with RIIα (Fig. 4C, middle panel).
Examination of the primary amino acid sequence in this
construct revealed an 18-amino acid sequence, SMDTAKD-
TLETIVREAGE (aa 3301–3318), that is predicted to form an
amphipathic helix (Fig. 4D, middle, designated H2). Substitu-
tion of leucine in position 3309 with a proline (L3309P)
completely disrupted interaction with RIIα (Fig. 4C, middle
panel). These results demonstrate the existence of a second
amphipathic helix H2 in myospryn.Fig. 7. Myospryn is a substrate for PKA. (A) Schematic of the N-terminal fragment o
sites between amino acids 138–158. (B) The putative PKA phosphorylation sites
subjected to an in vitro kinase assay using recombinant catalytic subunit of PKA. Dele
by PKA in vitro. (C) The N-terminal fragment of myospryn containing the PKA c
demonstrating that other endogenous kinases were not responsible for the phosphoryl
PKI, resulted in a loss of phosphorylation of the N-terminal fragment demonstrating
wildtype and mutant proteins was confirmed by blotting protein extracts with the anTo test whether eliminating both docking sites abolished
interaction between myospryn and PKA, a construct was
generated which removed both amphipathic helices H1 and
H2 in the context of the Spe fragment (Δ3,187–3,375).
Surprisingly, this construct effectively immunoprecipitated
RIIα (Fig. 5A and data not shown) suggesting the existence of
a third docking site for PKA between amino acids 3,375 and
3739. To confirm this finding two additional amino-terminal
deletions were generated, a construct consisting of amino acids
3375 through 3739 and a construct from amino acids 3474–
3739. Each construct was tested for its ability to interact with
RIIα. The co-IP experiments revealed that construct 3,375–
3,739 interacted with RIIα whereas construct 3474–3739 did
not (Fig. 4B) indicating a third anchoring site between amino
acids 3375 and 3474. Since a minimal construct coding for
amino acids 3375 through 3474 failed to express, a larger con-
struct was generated extending from amino acids 3375 to 3565
and tested for interaction with RIIα. This fragment was suf-
ficient to immunoprecipitate RIIα (Fig. 4B). Examination of this
region uncovered a predicted amphipathic helix between amino
acids 3421 and 3437, EINELVEEYRLTVKESC, (Fig. 4D, right,
designated H3). Substitution of cysteine at position 3,437 with a
proline in a construct expressing amino acids 3375–3565
(C3437P), which harbors amphipathic helix H3, severelyf myospryn (amino acids 73–743) shows three consensus PKA phosphorylation
are phosphorylated by PKA in vitro. The N-terminal myospryn fragment was
tion of all three sites from this myospryn fragment is unable to be phosphorylated
onsensus sites was incubated in the kinase assay buffer without PKA enzyme
ation. Incubation with recombinant PKA and the PKA-specific peptide inhibitor,
specificity for PKA. For all of the above experiments protein expression of the
ti-FLAG antibody.
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summarized in the schematic Fig. 5B, the above results confirm
the existence of three bona-fide PKA-anchoring domains in
myospryn each predicted to form an amphipathic helix and
independently capable of interacting with RIIα.
3.6. Evolutionary conservation of the PKA-anchoring region in
myospryn
To determine whether the PKA-anchoring function in myos-
pryn has been evolutionarily conserved we compared the carboxy-
terminal amino acid sequences of themouse, human, and zebrafish
orthologs ofmyospryn. Indeed, we identified all three amphipathic
helices to be evolutionarily conserved in these three species with
helix H3 exhibiting the highest degree of conservation (Fig. 6A).
To test whether zebrafish myospryn is capable of interacting with
RIIα we amplified the carboxy-terminal sequences from a 96-
h post-fertilization zebrafish embryo cDNA library and cloned this
fragment into pcDNA3-Myc. We then tested for interaction with
RIIα using co-IP in COS cells. As shown in Fig. 6B, zebrafish
myospryn interacted effectively with RIIα clearly demonstrating
conservation of AKAP function in myospryn.
3.7. Myospryn is an AKAP that is phosphorylated by PKA in
vitro
Given that some AKAPs can be regulated by PKA phosphor-
ylationwe searched themyospryn open reading frame for potential
PKA phosphorylation sites using the Motif Scan program
(scansite.mit.edu) [25]. This analysis revealed three sequences
located in the amino-terminal region of the protein that conform to
the consensus PKA recognition sequence, KRXS (Fig. 7A) [26]. A
FLAG-tagged amino-terminal construct (amino acids 73–743)
harboring these sites, KRGS142, RKGS150 and KRNS155, was
expressed in COS cells, immunoprecipitated with anti-FLAG
antibodies and subsequently used as a substrate in an in vitro
kinase assay with recombinant PKA catalytic subunit (New
England Biolabs) and γ-32P-ATP (Perkin Elmer). As shown in
Fig. 7B, this construct was phosphorylated by recombinant PKA
(left lane). As a negative control, the pcDNA3-FLAG vector was
transfected into COS cells and immunoprecipitated with anti-
FLAG was not phosphorylated by PKA (data not shown).
To further demonstrate specificity of PKA phosphorylation at
these particular sites a myospryn construct lacking these
sequences (amino acids 138–158) was expressed in COS cells,
immunoprecipitated and subjected to an in vitro kinase assay. As
shown in Fig. 7B, this deletion construct was unable to be
phosphorylated by PKA demonstrating the specificity of phos-
phorylation at one or all three of these sites (right lane). More-
over, subjecting these reactions to the PKA peptide inhibitor,
PKI (Promega), completely blocked phosphorylation on myos-
pryn (Fig. 7C, compare right lane to middle lane). An additional
negative control reaction incubated, under the same conditions,
in the absence of recombinant PKAwas unable to phosphorylate
myospryn (Fig. 7C, left lane). These results show that, in
addition to anchoring PKA, myospryn has the potential to serve
as a substrate for the cAMP signaling pathway in muscle.4. Discussion
In this study we demonstrate for the first time that the MEF2-
regulated gene, myospryn, encodes a muscle-specific protein
kinase scaffolding protein related to AKAP12 also known as
gravin/AKAP250/SSeCKS. Our study is also the first to report
that a member of the TRIM superfamily of proteins functions as
an anchoring protein for the cAMP-PKA signaling pathway. We
have shown that myospryn interacts specifically with the type II
regulatory subunit of PKA, RIIα, through three evolutionarily
conserved PKA anchoring domains, that it colocalizes with this
subunit at the costamere of striated muscle, and that it is
phosphorylated by PKA. Our study supports a previous finding
of a yeast two-hybrid interaction between RIIα and myospryn
(designated as genethonin III) [27]. Since proteins residing in
the peripheral Z-disc/costameric region have been implicated in
cardiovascular disease and skeletal myopathies [28,29] our data
suggest a new role for the cAMP-PKA signaling pathway in
modulating the function of this specialized micro-domain under
normal and pathological conditions in muscle.
Bioinformatics analysis revealed modest similarity between
myospryn and AKAP12/gravin/SSeCKS within a region
spanning 1500 amino acids. This region in AKAP12 harbors
a single amphipathic helix docking site for PKA. However, the
homologous region in myospryn does not contain a PKA
anchoring motif instead the binding sites for PKA are located
in the carboxy-terminal region of the protein. This finding is
not surprising since the primary amino acids constituting the
PKA anchoring domain are not strictly conserved within the
AKAP family [10–12]. Thus, the sequence similarity spanning
a larger region suggests that gravin and myospryn are
structurally related and may share common biological func-
tions beyond PKA anchoring. Along these lines, gravin
harbors binding sites for the G-protein coupled β-adrenergic
receptor [30] within the region homologous to myospryn
raising the possibility that myospryn may interact with this
receptor. These findings are particularly intriguing given the
central role of the β2-adrenergic receptor signaling in cardiac
muscle cell function and dysfunction [31]. Studies are
currently underway to test the ability of myospryn to modulate
G-protein coupled receptor signaling in muscle.
Our deletion mapping revealed the existence of three PKA-
anchoring domains in myospryn which interact exclusively
with the regulatory RIIα subunit. Removal or mutation of these
anchoring domains resulted in a loss of ability to interact with
RIIα. The amino acid residues contained within the three
binding domains are predicted to form amphipathic α-helices
further reinforcing the notion that these are authentic anchoring
sites for PKA. We have also demonstrated that the H1, H2, and
H3 docking sites are each independently capable of interacting
with RIIα possibly reflecting functional redundancy among the
binding sites. To our knowledge this is the first demonstration
that an AKAP harbors multiple binding sites for a single
regulatory subunit. There are examples of AKAPs harboring
multiple binding sites for PKA, however in these instances each
individual anchoring domain typically serves as a docking site
for one or more classes of PKA regulatory subunits [10–12,22].
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that this particular configuration of RII binding motifs imparts
specificity to myospryn distinguishing it from other AKAPs
within the same subcellular localization. Another possibility is
that the unique primary amino acid sequences within H1, H2,
and H3may have inherently different binding affinities towards
RIIα. Indeed, it is known that PKA anchoring domains from
various AKAPs not only exhibit different dissociation kinetics
between type I and type II regulatory subunits but also
differences in binding affinity within a single type of regulatory
subunit [10–12,22]. This remains a distinct possibility as our
coimmunoprecipitation assays were not designed to reveal
subtle differences in binding affinities between the three
anchoring sites.
Mapping of the myospryn PKA anchoring domains revealed
that these binding sites are embedded within the TRIM region
which also serves as an interaction platform for α-actinin,
dysbindin, and myospryn oligomerization [17,18]. Given the
numerous interactions within this region, some of which
overlap, it is unlikely that myospryn binds to these proteins
simultaneously in muscle. Rather, it is more likely that
myospryn binds to only a subset of these protein partners at
any given time. Indeed, a hallmark of AKAPs and other
scaffolding proteins is their dynamic ability to exchange protein
partners depending on the physiological conditions [10–
12,22,32].
Our studies reveal that myospryn represents a novel muscle-
specific AKAP. Prior to our discovery that myospryn interacts
with PKA the only known muscle-specific AKAP was mAKAP,
however, other broadly expressed AKAPs exist in muscle
[16,33,34]. While our work was in progress, a recent study
reported that the muscle-enriched, intermediate filament protein
synemin also interacts with a type II regulatory subunit of PKA
[35]. Clearly, the highly intricate cytoarchitectural organization
of striated muscle dictates a need for multiple AKAPs to
spatially restrict PKA enzymatic activity to the numerous
subcellular structures. In addition, several AKAPs are found
within the same subcellular location in muscle, suggesting that
each AKAP assembles its own unique combination of
interacting partners to provide PKA target specificity. The
peripheral Z-disc/costamere localization of myospryn places it
in an ideal environment for integrating cAMP-PKA signals
within this important micro-domain in striated muscle.
As PKA signaling has never been examined at the level of
the costamere it is not yet known which proteins are
phosphorylated by PKA. However, attractive candidates are
members of the dystrophin-glycoprotein complex (DGC). The
DGC resides in the costamere in skeletal and cardiac muscle and
there is increasing evidence of components of signaling
pathways interacting with proteins associated with the DGC
[36,37]. The discovery that myospryn functions as an AKAP
will allow us to examine in greater detail the potential substrates
for PKA and biological effects of PKA signaling in costameric
function. Therefore, a better understanding of the mechanisms
and means by which PKA signaling is regulated through
myospryn in muscle cells may provide insight into the
mechanisms contributing to various types of muscle disease.Acknowledgements
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